Skip to main content
PsyBio Therapeutics Corp. logo

PsyBio Therapeutics Corp. — Investor Relations & Filings

Ticker · PSYBF LEI · 549300KO32JSWBZIZP18 TSXV Manufacturing
Filings indexed 119 across all filing types
Latest filing 2023-08-31 Regulatory Filings
Country CA Canada
Listing TSXV PSYBF

About PsyBio Therapeutics Corp.

www.psybiolife.com

PsyBio Therapeutics Corp. is an intellectual property-driven biotechnology company focused on the discovery, design, and development of psycho-targeted therapeutics for mental and neurological conditions, including CNS disorders. The company develops a portfolio of novel psychoactive compounds and their analogues. A key differentiator is its proprietary platform utilizing genetically modified bacteria for the scalable, biosynthetic manufacturing of psychoactive molecules, such as tryptamines. PsyBio is actively engaged in preclinical studies and developing its own compounds, aiming to improve treatments for various psychologic and neurologic conditions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-08-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2023-08-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2023-08-31 English
Interim MD&A - English.pdf
Regulatory Filings
2023-08-31 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-08-31 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2023-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.